ClinicalMomentum Strong clinical-stage oncology focus with ST-001 nanoFenretinide and recent Phase 1a data presentation create opportunities for partnering with mid-to-late stage oncology and rare cancer programs seeking innovative delivery platforms.

ExpansionPotential FDA clearance for a second IND and ongoing expansion into small-cell lung cancer along with potential applicability to 15+ other cancers suggests doors for collaboration on companion trials, CRO partnerships, and co-development/native delivery strategy opportunities.

StrategicGrowth Sequential funding milestones and new leadership additions in medical, financial, and advisory roles indicate readiness for strategic partnerships, equity investments, and joint development agreements to accelerate trial expansion and manufacturing scale.

ManufacturingAdvantage Scalable nanomanufacturing capability paired with a clear path from lab to clinic positions SciTech as a potential supplier or collaborator for contract development and manufacturing organization (CDMO) engagements targeting nanoparticle delivery platforms.

DataDrivenOutreach Active dissemination of early clinical data at major venues (ASCO, USCLC) and ongoing investor communications highlight opportunities to engage researchers and investors with value-focused outreach, leveraging data to secure partnerships, licensing, or co-funded trials.